ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Mind Medicine MindMed Inc

Mind Medicine MindMed Inc (MNMD)

9.195
0.705
( 8.30% )
Updated: 12:20:39

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.007.909.500.008.700.000.00 %00-
2.007.107.504.107.300.000.00 %00-
3.006.106.404.836.250.000.00 %02-
4.005.105.504.205.300.000.00 %06-
5.004.104.304.304.201.7065.38 %123410:08:40
6.003.103.303.253.200.6826.46 %391,81210:58:57
7.002.152.352.402.250.9565.52 %251,07511:12:18
8.001.251.351.501.300.7087.50 %1322,05811:23:42
9.000.600.650.600.6250.45300.00 %1,4781,58412:19:17
10.000.200.250.250.2250.1066.67 %5851,02612:19:37
11.000.050.150.100.100.000.00 %52112:15:56
12.000.050.100.060.0750.0250.00 %17311:55:30

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.000.000.750.000.000.000.00 %00-
2.000.000.750.000.000.000.00 %00-
3.000.000.750.000.000.000.00 %00-
4.000.050.750.050.400.000.00 %02-
5.000.050.600.050.3250.000.00 %0252-
6.000.050.050.050.050.000.00 %101,33809:39:56
7.000.160.100.160.130.000.00 %0101-
8.000.050.150.130.10-0.22-62.86 %5017412:03:08
9.000.500.500.480.50-0.42-46.67 %292311:54:28
10.000.851.201.101.0251.052,100.00 %1310:12:51
11.000.752.850.001.800.000.00 %00-
12.002.603.400.003.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 0.1767
(152.43%)
1.03B
BCGBinah Capital Group Inc
$ 4.28
(115.06%)
17.43M
MFHMercurity Fintech Holding Inc
$ 2.0001
(55.05%)
1.2M
ALGSAligos Therapeutics Inc
$ 14.41
(41.41%)
2.03M
CONLGraniteShares ETF Trust GraniteShares
$ 67.80
(39.45%)
17.79M
RAPTRAPT Therapeutics Inc
$ 1.615
(-44.12%)
5.29M
SMSTTidal Trust II Defiance Daily Target 2x Short MSTR ETF
$ 2.90
(-36.54%)
4.67M
TRNRInteractive Strength Inc
$ 4.05
(-32.95%)
333.88k
VCIGVCI Global Ltd
$ 1.50
(-27.18%)
378.39k
SPNSSapiens International Corporation NV
$ 29.11
(-26.21%)
414.42k
CEROCERo Therapeutics Holdings Inc
$ 0.1767
(152.43%)
1.03B
TSLATesla Inc
$ 345.025
(7.41%)
123.13M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 21.89
(14.85%)
121.07M
NVDANVIDIA Corporation
$ 145.055
(-1.74%)
102.52M
HOVRNew Horizon Aircraft Ltd
$ 0.394
(35.86%)
100.85M

MNMD Discussion

View Posts
MomsSpaghetti MomsSpaghetti 3 hours ago
$MNMD Mind Medicine (MindMed)'s (MNMD) Buy Rating Reiterated at HC Wainwright - 55.00

https://www.marketbeat.com/instant-alerts/mind-medicine-mindmeds-mnmd-buy-rating-reiterated-at-hc-wainwright-2024-11-11/
👍️ 1
MomsSpaghetti MomsSpaghetti 4 hours ago
Pre Market Trading is nice!
👍️ 1
MomsSpaghetti MomsSpaghetti 2 days ago
Oh this is just getting started. Don't get me wrong I believe in the company long term, but this has the potential to go to 80-100 very quickly!!! - yes it will fall back to reality and then do it's natural climb as we progress through the year.

I see a buyout coming in 12-16 months. This is going to be amazing.
👍️ 1
BefallenKnight BefallenKnight 3 days ago
I think the squeeze happened. As of Oct 2024 there were about 10mm +/- short shares and a float of 70mm +/- shares. My guess is a lot of short shares were covered over the past 3 days leading to the 40% gain this week.

That said, MNMD has 70mm shares outstanding! That is an absurdly low float and very easy to lock up at such a low PPS. No reason this thing can ab-so-f*cking-loutely EXPLODE
😍 1
Jack Torrance Jack Torrance 3 days ago
Indeed.
😍 1
MomsSpaghetti MomsSpaghetti 3 days ago
Blackrock now owns 7% of MindMed

https://ir.stockpr.com/mindmed/sec-filings-email/content/0002012383-24-003562/ca60255c8850_110824.txt
👍️ 2
MomsSpaghetti MomsSpaghetti 3 days ago
Short term squeeze could happen. Range unknown. To infinity and beyond here.
👍️ 1
MomsSpaghetti MomsSpaghetti 3 days ago
This is going to short squeeze!
👍️ 1
MomsSpaghetti MomsSpaghetti 3 days ago
RFK Jr. Pledges To Legalize Marijuana And Psychedelics, Using Revenue To Fund Farms Where People Recovering From Drug Addiction Can Grow Organic Food

https://www.marijuanamoment.net/rfk-jr-pledges-to-legalize-marijuana-and-psychedelics-using-revenue-to-fund-farms-where-people-recovering-from-drug-addiction-can-grow-organic-food/

“I would legalize psychedelic drugs—some form of legalization,” he said, adding that he doesn’t necessarily envision a commercial market where anyone could visit a shop to buy the substances, but that there should be regulated access”
👍️ 1
MomsSpaghetti MomsSpaghetti 3 days ago
moving to 11.00 in the next 20-30 days
👍️ 1
MomsSpaghetti MomsSpaghetti 3 days ago
They have the cash to last them past these trials. That is what was needed. I understand why they did it prior but we are in the home stretch now.
👍️ 1
Jack Torrance Jack Torrance 3 days ago
Indeed. And I'm glad. They need to stop diluting.
👍️0
MomsSpaghetti MomsSpaghetti 3 days ago
Plus... cash runway into 2027. We are golden. Price targets range from 40-145

Huge range but amazing growth going to happen.
👍️ 1
Jack Torrance Jack Torrance 3 days ago
Great times ahead, gents. Phase 3 trial of MM120 for General Anxiety Disorder to commence by end of year, lasting approximately 12 weeks. And two other phase 3 trials for Major Depressive Disorder, also for MM120, to commence in 2025 and extend into 2026. All the results should be in by 2026, according to MindMed. I know some may be groaning, thinking we have to wait about another year. But when these trials are going good, the word tends to get out early and the fomo buying starts well before FDA approval. And with Trump and RFK Jr. both apparently behind psychedelics, that should push this sector, and MindMed, even further.

In short, things seem well in hand here. Just have to hold and wait for lift off.
👍️ 1
MomsSpaghetti MomsSpaghetti 4 days ago
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026--

https://www.businesswire.com/news/home/20241107702200/en/MindMed-Reports-Third-Quarter-2024-Financial-Results-and-Business-Updates

--On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025--

--Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--

--Company to host a conference call today at 4:30 p.m. EST--

November 07, 2024 04:01 PM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update.

“Management's Discussion and Analysis of Financial Condition and Results of Operations”
Post this
“This is a pivotal moment for MindMed as we prepare to initiate Voyage, our first Phase 3 study of MM120 ODT in GAD,” said Rob Barrow, Chief Executive Officer of MindMed. “Beyond Voyage, we are on track to initiate two additional Phase 3 studies: the Panorama study, our second trial in GAD, and the Emerge study, our first trial of MM120 ODT in MDD. Our Phase 3 development strategy leverages high-performing clinical trial sites from our Phase 2 study, as well as thoughtfully aligned protocols, which we expect to enable efficient enrollment across GAD and MDD. Our strong execution throughout the year has positioned us as a well-financed, late-stage clinical leader, set to launch three Phase 3 studies targeting two indications affecting approximately 51 million adults in the U.S. I could not be more pleased with our progress as we continue to build a high-performing organization dedicated to transforming the standard of care for people with brain health disorders.”

Program Updates and Anticipated Milestones

MM120 (lysergide D-tartrate) for GAD

The Company is on track to initiate the Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of adults with GAD in the fourth quarter of 2024. The Company expects the topline readout from the 12-week double-blind period (Part A) of Voyage in the first half of 2026.
The Phase 3 clinical program for MM120 ODT in GAD consists of two clinical studies: the Voyage study (MM120-300) and the Panorama study (MM120-301).
Both studies are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel group study assessing the efficacy and safety of MM120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT, subject to certain conditions for treatment eligibility.
Voyage is anticipated to enroll approximately 200 participants in the U.S. who will be randomized 1:1 to receive MM120 ODT 100 µg or placebo, and Panorama is anticipated to enroll approximately 240 participants (randomized 5:2:5 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo).
The primary endpoint for each study is the change from baseline in Hamilton Anxiety Rating Scale (HAM-A) score at Week 12 between MM120 ODT 100 µg and placebo.
Both studies are expected to employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. participant retention rate, variability of primary outcome measure) which allows for an increase of sample size up to 50% to maintain statistical power.
Panorama, the second Phase 3 study, will be conducted in the U.S. and Europe and is on track to initiate in the first half of 2025 with an anticipated topline readout from the 12-week double-blind period (Part A) in the second half of 2026.
MM120 (lysergide D-tartrate) for MDD

The Company is also developing MM120 ODT for the treatment of adults with MDD, beginning with the Emerge study (MM120-310) which, like the Phase 3 studies in GAD, is comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of MM120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT, subject to certain conditions for treatment eligibility.
Emerge is anticipated to enroll at least 140 participants (randomized 1:1 to receive MM120 ODT 100 µg or placebo).
The primary endpoint is the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between MM120 ODT 100 µg and placebo.
The Company expects to initiate Emerge in the first half of 2025 with an anticipated topline readout from the 12-week double-blinded period (Part A) in the second half of 2026.
The Company expects to conduct a second Phase 3 registrational study in MDD, with the study design and timing to be informed by the progress of Emerge and additional regulatory discussion.
MM402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD)

In October, the Company completed a Phase 1 study of MM402, a single-ascending dose study in adult healthy volunteers. The study was intended to characterize the tolerability, pharmacokinetics and pharmacodynamics of MM402. The Company expects to initiate further studies of MM402 for the potential treatment of ASD, with the exact timing and scope of such studies to be determined.
Third Quarter 2024 Financial Results

Cash Balance. As of September 30, 2024, MindMed had cash and cash equivalents totaling $295.3 million compared to $99.7 million as of December 31, 2023.

The Company believes that its cash and cash equivalents as of September 30, 2024, will be sufficient to fund the Company’s operations into 2027. Based on the Company’s current operating plan and anticipated R&D milestones, the Company expects its cash runway to extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD.

Net Cash Used in Operating Activities. For the nine months ended September 30, 2024, net cash used in operating activities was $53.8 million, compared to $43.8 million in the nine months ended September 30, 2023.

Research and Development (R&D). R&D expenses were $17.2 million for the quarter ended September 30, 2024, compared to $13.2 million for the quarter ended September 30, 2023, an increase of $4.0 million. The increase was primarily due to $2.1 million in expenses related to our MM120 program supporting the advancement into pivotal studies for the treatment of adults with GAD, $0.9 million in expenses related to our MM402 program, $0.6 million in internal personnel costs as a result of increasing research and development capacities, and an increase of $0.4 million in expenses related to preclinical activities.

General and Administrative (G&A). G&A expenses were $7.6 million for the quarter ended September 30, 2024, compared to $8.4 million for the quarter ended September 30, 2023, a decrease of $0.8 million. The decrease was primarily attributable to lower spending in legal and commercial activities, partially offset by an increase in stock-based compensation expense.

Net Loss. Net loss for the quarter ended September 30, 2024, was $13.7 million, compared to $17.9 million for the same period in 2023, a decrease of $4.2 million. The decrease was primarily due to changes in the fair value of warrants issued in our September 2022 underwritten offering of $5.3 million partially offset by an increase in research and development expense.

Conference Call and Webcast Reminder

MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s third quarter 2024 financial results. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MM120

MM120 (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors. MindMed is developing MM120, the tartrate salt form of lysergide, for GAD and MDD and is exploring its potential applications in other serious brain health disorders. Based on the significant unmet medical need in the treatment of GAD – especially in patients who do not respond to or tolerate currently available medications – along with the initial clinical data from Phase 2b and other research conducted by MindMed, the U.S. Food & Drug Administration (FDA) has designated MM120 for GAD as a breakthrough therapy. The MM120 ODT Phase 3 clinical development program includes the Voyage and Panaroma studies in GAD and the Emerge study in MDD. Additional clinical indications under consideration.

About MM402

MM402 is the Company’s proprietary form of R(-)-MDMA (rectus-3,4-methylenedioxymethamphetamine), being developed for the treatment of core symptoms of ASD. MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
👍️0
MomsSpaghetti MomsSpaghetti 4 days ago
This stock is going back to what is should be worth and then some. Buy out is coming... Fill your pockets while you can. FDA red tape getting removed.
👍️ 1
BefallenKnight BefallenKnight 4 days ago
Big F Up on MA and Dems
When it comes to drug policy Massachusetts really dropped the ball here for Democrats, as did Joe and Kamala for the past 4 years. From day one they should have made a priority of drug reform.

Now the trump administration may be the ones to capitalize on drug reform, effectively snatching the initiatives from the Democrats. I’m no fanboy of Elon, RFK Jr or Rogan but if these guys get it done that’s gonna be a massive blemish on the Democrats, particularly Schumer and those claiming to be pro drug reform only to repeatedly drag their feet until nothing gets done.
👍️0
MomsSpaghetti MomsSpaghetti 4 days ago
No shit. You don't need to be a lawyer to make money from investments. You can buy stocks, sell them, hold them, buy calls and puts, you can read headline and follow their herd.

So shut quit with your parenting here and contribute to the conversation about the company. You want to talk policies fine.

But but don't personally attack people.
👍️0
Giovanni Giovanni 4 days ago
You did not go to law school!

Integrating psychedelic treatment into clinical practice will require peeling back many layers of legal prohibition, FDA approval, clarifying prescribing guidelines, and developing treatment models that work for drug makers, physicians, and patients.
Can hallucinogens be prescribed?
Many hallucinogens are Schedule I under the Controlled Substances Act, meaning that they have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

Are psychedelic drugs legal in any state?
Oregon voters passed a 2020 ballot measure making it the first state to both decriminalize psilocybin and also legalize its supervised use. Colorado followed with a similar measure in 2022.

Why does a new Tesla not smell like a new car?

It has Elon Musk.
👍️0
MomsSpaghetti MomsSpaghetti 5 days ago
We don't need it legalized - just needs to be rescheduled! You have no idea what you are talking about.

Plus RFK Jr is for psychedelics.
Trump is for right to try

I'm not for these folks but it will bode very well for this stock.
👍️ 2
Savannah-Marc Savannah-Marc 5 days ago
RFK Jr. had some very interesting tweets on the psychedelic space...
👍️ 2 😎 1
Giovanni Giovanni 5 days ago
Election Results: Question 4 - voters reject legalization of psychedelic drugs
Updated: Nov. 06, 2024, 7:19 a.m.|Published: Nov. 06, 2024, 6:27 a.m.

https://www.masslive.com/politics/2024/11/mass-election-results-question-4-voters-reject-legalization-of-psychedelic-drugs.html

Massachusetts is one of the most liberal and Democratic-leaning states in the country. It was the first state where same-sex marriage became legal in 2004. It has the highest percentage of adults with college degrees of any state in the country.
👍️0
MomsSpaghetti MomsSpaghetti 5 days ago
Party on!
👍️ 1
MomsSpaghetti MomsSpaghetti 5 days ago
shooting star morning!
👍️ 1
MomsSpaghetti MomsSpaghetti 5 days ago
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

https://seekingalpha.com/article/4732842-mind-medicine-two-pathways-created-from-one-pipeline-clinical-candidate
👍️ 1
MomsSpaghetti MomsSpaghetti 1 week ago
Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study

https://d1io3yog0oux5.cloudfront.net/_8e941dfd4bfcdc0589730491d3305c84/mindmed/db/2265/21484/pdf/MindMed+Psych+Congress+2024+Rapid+and+Durable+Response+to+a+Single+Dose+of+MM120+%28Lysergide%29+in+Generalized+Anxiety+Disorder.pdf



Conclusions

This trial was the first to assess the dose-dependent efficacy of LSD without concurrent psychedelic-assisted therapy. The study demonstrated that, for a single treatment with MM120, 100 µg is the optimal dose to bring forward into future research, as it showed a clinically meaningful and statistically significant improvement in Generalized Anxiety Disorder (GAD) and had a favorable adverse event (AE) profile compared to 200 µg.

This treatment effect was observed as early as the day following treatment (CGI-S) and sustained through the end of the study at week 12. The results support progression toward pivotal trials of MM120 100 µg for the treatment of GAD to confirm efficacy and evaluate the durability of the effect.

MM120 100 µg achieved the highest level of clinical activity at the primary endpoint, with a 7.6-point reduction in Hamilton Anxiety Rating Scale (HAM-A) compared to placebo at week 4. In contrast, the week 4 HAM-A score reductions for 25, 50, and 200 µg were 3.4, 0.9, and 5.5, respectively. The HAM-A score reduction with 100 µg was more than twice that observed in clinical trials for other GAD treatments. Further, at week 4, MM120 100 µg exhibited an effect size of d=0.88, while a meta-analysis of 21 placebo-controlled trials for GAD revealed that current medications provide only modest benefits, with an overall d=0.39.

Comparatively, benzodiazepines have shown acute efficacy in patients with GAD but require repeat dosing to prolong effects and are associated with a risk for dependency and unwelcome side effects.

Additionally, higher doses of MM120 also demonstrated improvement in depressive symptoms. Many patients with GAD have comorbid depressive symptoms; in our study, at week 1, the 100 µg dose showed a placebo-adjusted reduction of 6.6 points in Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline. These improvements had a rapid onset compared to standard-of-care medications for depressive disorders.

MM120 was well tolerated by most participants, with AEs that were primarily mild and temporary, mainly occurring on the dosing day, and were consistent with the drug class and prior studies. There were no serious AEs or suicide-related safety signals.
👍️ 1
MomsSpaghetti MomsSpaghetti 1 week ago
Functional Unblinding Evaluation of Central Raters in a Large Psychedelic Clinical Trial

https://d1io3yog0oux5.cloudfront.net/_8e941dfd4bfcdc0589730491d3305c84/mindmed/db/2265/21485/pdf/MindMed+Psych+Congress+2024+Functional+Unblinding+Evaluation+of+Central+Raters+in+a+Large+Psychedelic+Clinical+Trial.pdf

Conclusion

This is the first large psychedelic RCT to collect and report data on CR unblinding. The results indicate that utilizing CRs appears to be a viable method for reducing functional unblinding in studies where the investigational product (IP) under study can produce acute subjective effects.

Given the number of active arms in this study, it is possible that future studies assessing CR unblinding may encounter more functional unblinding of CRs if the study includes only one active treatment group versus placebo.

Future studies should continue to assess functional unblinding of CRs, rather than focusing solely on participant and site staff blinding. Additionally, future analysis of unblinded study data should explore the relationship between treatment allocation and CR scoring.
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago
Functional and Sexual Disability, and Quality of Life After One Dose of MM120
(Lysergide) in Adults With Generalized Anxiety Disorder

https://d1io3yog0oux5.cloudfront.net/_8e941dfd4bfcdc0589730491d3305c84/mindmed/db/2265/21486/pdf/MindMed+Psych+Congress+2024+Funcation+and+Sexual+Disability%2C+Quality+of+Life+After+One+Dose+of+MM120+in+Adults+with+Generalized+Anxiety+Disorder.pdf
👍️ 1
MomsSpaghetti MomsSpaghetti 2 weeks ago
Nice HOM
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago
Gio you are mistaken... Schedule I drugs that have been used for medical purposes, primarily under strict regulations and often in research settings. For example, cannabis is classified as a Schedule I drug in the U.S. but has been legalized for medical use in many states. Similarly, substances like psilocybin (found in magic mushrooms) and MDMA are being researched for their potential therapeutic benefits, particularly in treating conditions like PTSD and depression.

As for rescheduling, substances can be moved between schedules based on new evidence regarding their safety and medical utility. For instance, in 2020, the Drug Enforcement Administration (DEA) approved the use of a cannabis-derived medication, Epidiolex, which contains CBD and is used to treat certain forms of epilepsy. Other drugs, like ketamine (think Spravato from J&J), have also seen shifts in their scheduling due to recognized medical uses.

The scheduling system is dynamic and can change as more research becomes available and societal views shift.

To be honest it is why I invest here becuase when this happens this stock will be white hot.
👍️ 1
MomsSpaghetti MomsSpaghetti 2 weeks ago
hard headed agenda...
👍️0
Jack Torrance Jack Torrance 2 weeks ago
And cocaine, heroin and a slew of other drugs are also restricted, yet derivative compounds find their way into prescription meds. FDA has approved these trials. They wouldn't do that if the compound MindMed was developing is banned for medicinal use. Get a clue, loser.
👍️0
Giovanni Giovanni 2 weeks ago
By Law the government has imposed restrictions on psychedelics


it is beyond MindMed's control as they have to act in accordance with U.S. and State law

No matter how wishfull your thinking!
👍️0
Jack Torrance Jack Torrance 2 weeks ago
Yes, that's the definition of an FDA approved drug for patient use. Can YOU read?
👍️0
Giovanni Giovanni 2 weeks ago
Can you read?

If it gets approval it will be with medical professionals being in attendance every second of the TRIP .
👍️0
Jack Torrance Jack Torrance 2 weeks ago
I.e., no “intervention” by the monitors that is prescribed, standardized, or expected to offer measurable therapeutic value

Except that it does. As evidenced by phase 2 and phase 2b, and the FDA approval for phase 3.
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago


Good reminder in this piece that, while people within psychedelics-savvy communities nitpick about “therapy” vs “support” phrasing, the leading companies all view themselves as operating within a functionally equivalent paradigm

“Other developers, such as Compass Pathways and Cybin, have made similar moves, focusing more on the drug itself rather than combining it with in-depth psychotherapy.”

I.e., no “intervention” by the monitors that is prescribed, standardized, or expected to offer measurable therapeutic value
👍️0
Jack Torrance Jack Torrance 2 weeks ago
How did synthetic marijuana get approved? How did all the opioid-based pain killers get approved? How did medical grade cocaine get approved? How did methadone get approved? How did medical methamphetamine get approved? How did ketamine get approved? Etc, etc, etc...

Also, MM120 is an LSD derivative, not 100% LSD. It's a novel compound in FDA trials with FDA Breakthrough Therapy Designation. Do you think the FDA would have even approved the start of the trials if it was a compound that could never be prescribed for patient use? Use your head.

And it's legislation, not legistration, brainlet.

https://www.webmd.com/mental-health/news/20240326/fda-opens-the-door-clinical-use-lsd

The FDA’s breakthrough therapy designation speeds up the development and review of drugs intended to treat a serious condition where early evidence indicates the drug may be better than available therapies. The acceleration of this process may well lead to FDA approval of LSD for treating generalized anxiety disorder within the next few years. That approval would automatically legalize the clinical use of LSD.
👍️ 2 💯 1
Giovanni Giovanni 2 weeks ago
Did you read the Massachusetts ballot question? I think not!

Mind med needs legistration , good luck with this!

Here you go:

Is LSD legal?



Tufts Medical: https://www.google.com/search?q=Tufts+Medical&rlz=1CABBMB_enUS1125&sourceid=chrome&ie=UTF-8



No, LSD is not legal in the United States. It is classified as a Schedule I drug, and the United Nations also lists it as a Schedule 1 controlled substance. LSD has no appvroed medical uses.
LSD was first synthesized in 1938 by Albert Hofmann, a Swiss chemist. It was studied in the 1950s and 1960s, and was used experimentally to treat schizophrenia and alcoholism. However, its association with the counterculture movement of the 1960s led to its classification as a Schedule I drug in 1968.
Despite its legal restrictions, LSD remains influential in scientific and cultural contexts. Its therapeutic potential has been explored, particularly in treating mental health disorders.

-------------------------------------------
Question 4: Legalizing psychedelic drugs

Our verdict: No

Psychedelic drugs, including psilocybin, DMT, psilocyn, mescaline and ibogaine, are currently illegal both federally and statewide. A “Yes” vote on Question 4 would make them legal at the state level, allowing them to be grown and shared by Massachusetts residents, and clearing the way for the creation of therapy centers where residents could use psychedelics under the guidance of medical professionals. Drugs like psilocybin have been shown to effectively treat a variety of mental health conditions, but much less is known about the other drugs. While the creation of therapy centers would be a step in the right direction, the proposed plan for at-home and personal use comes with very little oversight to ensure users’ safety. Allowing residents to grow psychedelics and share them with anyone is a dangerous proposal, since many of these drugs are associated with life-threatening cardiac problems and long-lasting neurological effects. Given that the therapy centers will be expensive and may take years to open, most residents will likely opt for home use, bringing heightened risks to an already legally fraught issue.
👎️ 1
MomsSpaghetti MomsSpaghetti 2 weeks ago
Can LSD break the 20-year drought in anxiety treatment?
As MindMed advances its novel LSD therapy to a Phase 3 trial, the company aims to transform treatment for generalized anxiety disorder.

https://www.drugdiscoverytrends.com/lsd-phase-3-trials-anxiety-treatment-mindmed/
👍️ 1
Giovanni Giovanni 3 weeks ago
Massachusetts has a ballot question on psycadelics
legalize them
and have them given only with professional health advisors present at all times.
No one will be given psychedelics to take without health providers present.
👍️ 1
Giovanni Giovanni 3 weeks ago
edit
👍️0
LORTAP KCOTS LORTAP KCOTS 3 weeks ago
UP!!
👍️0
MomsSpaghetti MomsSpaghetti 3 weeks ago
Moving
👍️0
Giovanni Giovanni 4 weeks ago
No just misguided
🫡 1
MomsSpaghetti MomsSpaghetti 4 weeks ago
This has a target of 20.00 and it will be much higher than that when approved.
👍️ 1
MomsSpaghetti MomsSpaghetti 4 weeks ago
I'm deep :)
👍️0
LORTAP KCOTS LORTAP KCOTS 4 weeks ago
I’ve got 3000 shares all are up at least double now
👍️ 1
LORTAP KCOTS LORTAP KCOTS 4 weeks ago
This is moving up so let’s celebrate that if you are invested you are getting rewarded
👍️ 1
MomsSpaghetti MomsSpaghetti 4 weeks ago
Are you trying to imply that I am dense? This is not the cannabis market. To which I will agree with you is an absolute nightmare. This is entirely different. You can't even compare the two.
👍️0

Your Recent History

Delayed Upgrade Clock